Table 4.

Sensitivity and specificity of potential diagnostic biomarkers in pancreatic cancer

Biomarkers	Optimum cut-off	Sensitivity (%)	Specifificity (%)
PC vs. Controls
CA19-9	≥ 57 U/mL	80.21	75
ATX	≥ 286 ng/mL	78.95	80
LPA	≥ 10.7 µg/mL	91.74	69.4
TS1 + TS2 vs. Controls
CA19-9	≥ 57 U/mL	77.33	75
ATX	≥ 286 ng/mL	65.33	80
LPA	≥ 10.7 µg/mL	80.67	69.4
TS3 + TS4 vs. Controls
CA19-9	≥ 57 U/mL	82.26	75
ATX	≥ 286 ng/mL	89.6	80
LPA	≥ 10.7 µg/mL	95.65	69.4

Controls: healthy volunteers + benign pancreatic diseases

TS, tumor stage